Cofetuzumab pelidotin

Cofetuzumab pelidotin

Monoclonal antibody
Type	?
Source	Humanized (from mouse)
Target	protein tyrosine kinase 7
Clinical data
Other names	PF-06647020
ATC code	none
Identifiers
CAS Number	1869937-48-3
ChemSpider	none
UNII	249EAP69MT
KEGG	D11118
Chemical and physical data
Formula	C6774H10418N1778O2096S46
Molar mass	151776.97 g·mol−1

Cofetuzumab pelidotin (INN; ^[1] development code PF-06647020) is an experimental antibody-drug conjugate in development for the treatment of cancer. It was created by Stemcentrx and is being developed by Pfizer. ^[2] The drug is an anti-PTK7 monoclonal antibody linked to auristatin-0101, an auristatin microtubule inhibitor. ^{[3] [4]}

Antibody-drug conjugates use a monoclonal antibody that binds to tumors cells linked to a cytotoxic drug that then kills the cells. This allows the drug to selectively target the cells that the antibody binds to.^{[ citation needed ]}

PTK7 is expressed by many tumors, including ovarian cancer, breast cancer, and non-small cell lung cancer. ^[5] Early clinical trial results show a 50% response rate in patients with triple negative breast cancer and an almost complete response in ovarian tumors resistant to platinum-based chemotherapies. ^[6]

References

1. World Health Organization (2017). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 117" (PDF). WHO Drug Information. 31 (2).
2. Statement On A Nonproprietary Name Adopted By The USAN Council - Cofetuzumab Pelidotin, American Medical Association.
3. "PF-06647020 Archives – ADC Review ADC Review". Adcreview.com. Retrieved 2017-05-22.
4. "Pfizer Oncology: ADC Development Overview (2016) – ADC Review ADC Review". Adcreview.com. Retrieved 2017-05-22.
5. "Antibody-Drug Conjugates (ADCs)" (PDF). Pfizer Oncology.
6. Patrick M (2016-06-28). "Why AbbVie Expects PTK7 to Enhance Its Oncology Capabilities". Market Realist. Retrieved 2017-05-22.